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Background: Neuroblastoma is a paediatric tumour originated from sympathoadrenal precursors and 
characterized by its heterogeneity and poor outcome in advanced stages. Intra-tumoral cellular hetero- 
geneity has emerged as an important feature in neuroblastoma, with a potential major impact on tumour 
aggressiveness and response to therapy. CD44 is an adhesion protein involved in tumour progression, 
metastasis and stemness in different cancers; however, there has been controversies about the signiﬁ- 
cance of CD44 expression in neuroblastoma and its relationship with tumour progression. 
Methods: We have performed transcriptomic analysis on patient tumour samples studying the outcome 
of patients with high CD44 expression. Adhesion, invasion and proliferation assays were performed in 
sorted CD44high neuroblastoma cells. Tumoursphere cultures have been used to enrich in undifferenti- 
ated stem-like cells and to asses self-renewal and differentiation potential. We have ﬁnally performed in 
vivo tumorigenic assays on cell line-derived or Patient-derived xenografts. 
Findings: We show that high CD44 expression is associated with low survival in high-grade human neu- 
roblastoma, independently of MYCN ampliﬁcation. CD44 is expressed in a cell population with neural 
crest stem-like features, and with the capacity to generate multipotent, undifferentiated tumourspheres 
in culture. These cells are more invasive and proliferative in vitro. CD44 positive cells obtained from 
tumours are more tumorigenic and metastatic, giving rise to aggressive neuroblastic tumours at high fre- 
quency upon transplantation. 
Interpretation: We describe an unexpected intra-tumoural heterogeneity within cellular entities express- 
ing CD44 in neuroblastoma, and propose that CD44 has a role in neural crest stem-like undifferentiated 
cells, which can contribute to tumorigenesis and malignancy in this type of cancer. 
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ish Ministry of Science and Innovation SAF program (SAF2016-80412-P), and the European Research Coun- 
cil (ERC Starting Grant to RP). 
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Neuroblastoma originates during neural crest development and
s characterized by a great heterogeneity. At the cellular level, these
aediatric tumours contain phenotypically divergent cells which
ave been classiﬁed transcriptionally into an adrenergic/neuronalunder the CC BY-NC-ND license. 
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s  cell population and an undifferentiated, neural crest-like mes-
enchymal cell population. These later cells are thought to be more
aggressive and resistant to therapy. CD44 is an adhesion trans-
membrane glycoprotein that mediates cell responses to the cel-
lular microenvironment, regulating cell growth, differentiation and
motility. Despite its relationship with tumour progression and ag-
gressiveness in other tumours, its role in neuroblastoma has been
controversial. 
Added value of the study 
We show that high CD44 expression on stage 4 NB pa-
tient tumours can be indicative of low survival. We demon-
strate that CD44 is highly expressed in undifferentiated, multi-
potent neural crest-like NB cells that are highly tumorigenic and
metastatic in vivo. High CD44 expression delineates the aggressive
undifferentiated/neural-crest-like cell population in neuroblastoma.
Implications of all the available evidence 
We help to clarify the controversies around CD44 expression in
NB at the cellular level postulating that CD44 could have a role
not only in terminally differentiated glial cells but also in neural
crest-like undifferentiated cells that can contribute to tumorigen-
esis. We offer new possibilities to isolate and characterize these
cells, explore their contribution to neuroblastoma relapses and ag-
gressiveness and promote their targeting. 
1. Introduction 
Neuroblastoma (NB) is a paediatric tumour that originates from
sympathoadrenal precursors during neural crest development [ 1 , 2 ].
It is characterized by a great heterogeneity, ranging from spon-
taneously regressing tumours to metastatic aggressive forms that
are incurable to date. Despite recent improvements in patient risk
stratiﬁcation and genetic proﬁling, neuroblastoma is still the most
lethal extracranial solid tumour in children. 
Currently available prognostic markers for NB (ampliﬁed MYCN,
loss of heterozygosity in chromosome 1p or DNA ploidy, among
others) fail to predict the outcome of all patients eﬃciently. Am-
pliﬁcation of the MYCN oncogene is the best prognostic factor to
date and is associated with poor outcome. However, this ampli-
ﬁcation is only found in approximately 22% of neuroblastoma tu-
mours [ 3 , 4 ]. Current approaches frequently fail to correctly classify
the rest of patients with unfavourable course, indicating the need
for new markers or the re-evaluation of existing ones [ 5 , 6 ]. More-
over, there is still an incomplete understanding of the biology of
this malignancy at the cellular level, making diﬃcult to ﬁnd thera-
peutically relevant molecular targets. 
Neuroblastomas seem to recapitulate neural crest development,
with the formation of multiple cellular lineages after spontaneous
or induced differentiation from neural crest progenitors. The de-
gree of differentiation and stromal content has allowed the histo-
logic stratiﬁcation of patients into risk-groups, with most aggres-
sive tumours being the most undifferentiated ones [ 7 , 8 ]. At the
cellular level, these paediatric tumours typically contain phenotyp-
ically divergent cells, with at least a neuroblastic/adrenergic pop-
ulation together with a non-neuronal/mesenchymal component,
which are both supposed to share a common origin [9] . More re-
cently, transcriptional proﬁling on neuroblastoma tumours and cell
lines have conﬁrmed this heterogeneity, showing the existence of
at least two main cell identities: an undifferentiated, neural crest-
like mesenchymal cell and an adrenergic committed cell [ 10 , 11 ]. 
CD44 is an adhesion transmembrane glycoprotein that medi-
ates cell responses to the cellular microenvironment, regulating
cell growth, differentiation and motility. This protein works as thePlease cite this article as: F.M. Vega, A. Colmenero-Repiso and M.A. 
associated with tumour aggressiveness and poor survival in neuroblast
10.041 ain receptor for the extracellular matrix ligand hyaluronic acid
HA) as well as other extracellular matrix components. CD44 also
cts as co-receptor for other signalling proteins like MET or inte-
rins [12] . This adhesion protein has been described to have a role
n tumour progression and has been linked to metastatic spread-
ng in various tumours such as colon or breast carcinomas [13–15] .
y contrast, CD44 expression presents an inverse correlation with
umour progression in other tumours like prostate carcinoma or
euroblastoma [ 16 , 17 ]. TCGA (The Cancer Genome Atlas) expres-
ion data shows a higher expression in human tumours compared
ith healthy tissues in colon adenocarcinoma, glioblastoma, re-
al cancer, amyloid leukaemia, ovarian and stomach cancer, among
thers. Meanwhile there is lower expression in thymomas, uterine
nd endometrial carcinoma tumours. The reasons for this cancer
ype-dependent discrepancy are not clear. This panorama is further
omplicated due to the existence of CD44 splice variants with dif-
erent functions in tumorigenesis, but whose relevance in NB is not
et clear [18–21] . 
CD44 has also been associated with the differentiation status of
eural precursor cells, being highly expressed in differentiated cells
f the glial lineage. NB cell differentiation to Schwann-like cells is
ormally associated to improved prognosis and increased CD44 ex-
ression [ 18 , 22 , 23 ]. In fact, CD44 expression was identiﬁed prefer-
ntially in a group of neuroblastoma patients with favourable out-
ome and maturing phenotype [24] . These observations, and the
act that MYCN directly represses CD44 expression [17] , explain
hy, in neuroblastoma, the lack of overall CD44 expression is a
tatistically signiﬁcant factor for poor prognosis [ 18 , 25 ]. However,
atients with CD44 + stage 4 tumours still behave quite poorly, and
he presence of CD44 expression does not allow a deﬁnitive low-
rade stratiﬁcation [26] . Furthermore, there is a minor CD44 pos-
tive cell population still present in stage 4 undifferentiated neu-
oblastomas, whose role, if any, remains to be established. Hence,
here is a clear need for the clariﬁcation of CD44 function at the
ellular level in neuroblastoma tumours with CD44 expression and
oor outcome. 
Given these preliminary evidences, we decided to shed light
n the function of CD44 in NB cells, especially in MYCN non-
mpliﬁed, high grade tumours. We describe here that CD44 is
ighly expressed in undifferentiated, multipotent neural crest-like
B cells that are highly tumorigenic and metastatic in vivo. More-
ver, we show that high CD44 expression on stage 4 NB patient tu-
ours is indicative of low survival. We postulate that CD44 could
ave a role not only in terminally differentiated glial cells but also
n neural crest stem-like undifferentiated cells that can contribute
o tumorigenesis, clarifying the controversies around CD44 expres-
ion in NB at the cellular level. 
. Materials and methods 
.1. Gene expression analysis 
CD44 gene expression analysis was performed with R2:
enomics Analysis and Visualization Platform ( http://r2.amc.nl;
cademic Medical Centre, Amsterdam). Human neuroblastoma
atasets used were GEO IDs GSE45547 (649 patient samples) and
SE90805 (34 samples, including neuroblastoma cell lines with
esenchymal state (7), adrenergic state (22) or human neural crest
ell lines (5) [11] . INSS stratiﬁcation system is used on these collec-
ions dividing tumours into stages 1, 2, 3 and 4, with 4 being the
ost aggressive. INRG stratiﬁcation system is used on the home
atient samples collection, dividing tumours into stages MS, L1,
2 and M, with M being the most aggressive. CD44hi expression
ut-off in survival curves is stablished according to CD44 expres-
ion distribution, established on the samples with a CD44 expres-Gómez-Muñoz et al., CD44-high neural crest stem-like cells are 
oma tumours, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019. 
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aion value above the 10th percentile of the distribution, and with
 minimal group size of 8 samples. 
.2. Cell culture 
SK-N-SH and SK-N-DZ are spontaneously immortalized, human
B cell lines that have not been subjected to selection in culture
nd present a mixed population reminiscent of neuroblastoma cell
eterogeneity, with neuronal-like cells and more spread glial-like
r undifferentiated cells [ 27 , 28 ]. They were obtained from ECACC
Salisbury, UK) and grown in DMEM supplemented with 10% FCS.
I-M-EN and GI-CAN are also heterogeneous cell neuroblastoma
ell lines and were obtained from the laboratory of Dr. M. Ponzoni
Genova, Italy). They were grown on DMEM and RPMI respectively,
upplemented with 10% FCS. CHLA-15 and CHLA-20 cell lines were
btained from the Children’s Oncology Group (COG) Cell Line and
enograft Repository (Texas Tech University Health Sciences Cen-
er) and grown on IMDM media + 10% FBS. NB39T and NB48T PDX
rimary cell lines were obtain from PDXs after mechanical dissoci-
tion and culture on IMDM + 15%FBS. All media were supplemented
ith 2 mM glutamine, 100 μg/ml streptomycin and 100 U/ml peni-
illin. Cells were also cultured, when indicated, in Neural Crest
omplete media (NCM) composed of d -MEM:F-12 + 15% FBS, 1%
2 supplement, 2% B27 supplement, 1% penicillin/streptomycin (all
rom Gibco, Paisley, UK), 10 ng/ml human FGF, 20 ng/ml human
GF-1, and 20 ng/ml human EGF (R&D Systems, Minneapolis, MN,
SA). Serum deprived NCM (NCMlow) was similar but without FBS.
.3. Immunoﬂuorescence and IHC 
For immunoﬂuorescence, cells or frozen sections were ﬁxed
ith 4% paraformaldehyde, permeabilized with 0.2% Triton X-
00 in PBS, blocked with 1% BSA in PBS and incubated with
he corresponding antibodies. Antibodies used were: S100 β ( α-
ouse Sigma or α-goat R&D; 1:500), CD44 (BD, San Jose, CA,
SA; 1:500), DDC (Cell signalling Technology, Hitchin, UK; 1:500),
FAP (DAKO, Carpinteria, CA, USA; 1:500), Nestin ( α-mouse R&D
r α-rabbit Millipore; 1:10 0 0), αSMA (Sigma; 1:10,0 0 0), CD114
PE-conjugated α-mouse BDPharmigen; 1:500) and Tuj1 (Sigma;
:20 0 0). Alexa546-ﬂuor phalloidin was used for F-actin visual-
zation and DAPI used for nuclear staining (Life Technologies,
arlsbad, CA, USA). Secondary antibodies used were Alexa568-
oat- α-mouse-IgG, Alexa568-goat- α-rabbit-IgG, Alexa488-donkey- 
-rabbit-IgG, Alexa633-sheep- α-goat-IgG and Alexa488-donkey- α-
ouse-IgG (Life technologies; 1:500). Images were acquired on an
piﬂuorescence (Olympus BX-61, Tokyo, Japan) or confocal (LSM
10, Zeiss, Oberkochen, Germany) microscope. 
For immunohistochemistry staining, paraﬃn embedded sections
5 μm) were obtained from tissues, hydrated, treated for antigen
etrieval with citrate buffer and incubated with the correspond-
ng antibodies. Vectastain ABC kit and DAB peroxidase substrate
it (Vector Laboratories, Burlingame, CA, USA) were used follow-
ng recommended procedures. Anti-nuclein antibody (Cell Signal-
ng; 1:10 0 0) was used to speciﬁcally mark human cells. 
.4. Fluorescence-activated cell sorting (FACS) 
Flow cytometry analyses and sorting were performed in a
ytometer BD FACS Aria (BD, Franklin Lakes, NJ, USA). Cells
ere detached with versene, resuspended in FACS medium (L15
edium + BSA 2 mg/ml, 1% Hepes and 1% penicillin/streptomycin)
nd incubated with the corresponding primary antibody for 40 min
t 4 ºC, followed by secondary ﬂuorescently labelled antibody for
0 min when necessary. Antibodies used were CD44 (BD, San Jose,
A, USA; 1:500), CD114 (PE-conjugated α-mouse BDPharmigen;
:500), c-kit (PE-conjugated, clone A3C6E2, Miltenyi Biotec; 1:500),Please cite this article as: F.M. Vega, A. Colmenero-Repiso and M.A. 
associated with tumour aggressiveness and poor survival in neuroblast
10.041 D133 (AC133 pure human Miltenyi Biotec; 1:300) and Alexa488-
onkey- α-mouse-IgG (Life Technologies; 1:500). Cells highly posi-
ive and negative for CD44 staining were sorted and used for sub-
equent experiments. Gating strategy considered CD44 expression
istribution levels in each cell line, deﬁning the population with
igh CD44 expression compared to negative cells. 
.5. QPCR 
RNA was extracted from tumourspheres or cell cultures us-
ng RNeasy micro kit (Qiagen, Chadstone Centre, VIC, Australia).
DNA was synthesized with the QuantiTec Reverse transcription
it (Qiagen) and Real-time quantitative PCR was performed in an
BI Prism 7500 Sequence Detection System using the thermocy-
ler conditions recommended (Applied Biosystems, Grand Island,
Y, USA). Detection was performed with SYBR Green PCR Master
ix and analysis with the Ct method. Oligonucleotides used can
e seen on Supplementary Table S1. 
.6. Tumoursphere formation assay 
For tumoursphere formation, cells were cultured in ultra-low
inding 6-well plates (Corning, NY, USA) at 50 0 0 cells per well
2.5 cells/ μl) in Neural Crest media (NCM) or serum deprived NCM
NCMlow), as indicated. Tumourspheres were allowed to form for
 days before imaging and collection for OCT inclusion, seeding
n top of adherent substrate or mechanical dispersion after 0.02%
rypsin treatment. For single-cell tumoursphere formation assays,
ingle cells (1 cell per well) were sorted onto single wells from
ltralow binding 96-well plates (Corning) with 100 μl neural crest
omplete medium, and grown 10–15 days before quantiﬁcation and
maging of tumourspheres. Except where indicated, imaged and
uantiﬁed tumourspheres were from second passages. TS forma-
ion eﬃciency is an indication of the percentage of TS forming cells
n the original cell culture and is deﬁned as the percentage of orig-
nally seeded cells in clonogenic dilution conditions that success-
ully form TS. Tumourspheres in suspension were concentrated in
he ﬁeld of view before imaging. 
.7. Adhesion, spreading, migration and proliferation assays 
Sorted cell cultures were detached with Versene and seeded on
ulture plates coated with 100 μg/ml Matrigel (BD Biosciences) or
ncoated. For adhesion assay, plates were washed with PBS, and
ells were ﬁxed and stained with Crystal violet solution 20 min af-
er seeding. Adhesion is expressed as the number of adhered cells
er condition after washing, relative to the ones found to adhere
rom the CD44hi population on TC plastic, which was set to 100%
or normalization. For cell spreading, cells were allowed to spread
or 1 h before ﬁxing with paraformaldehyde without washing. Cells
ere then stained for F-actin, and area quantiﬁed with Cell Proﬁler
oftware [29] . More than 100 cells from at least three different ex-
eriments were analysed. 
For migration studies in 3D, cells were mixed with Matrigel
5 μg/ml) and placed on Chemotaxis 3D microslides (Ibidi, Martin-
ried, Germany). Bright ﬁeld images were acquired at 37 °C every
 min for 24 h on a Nikon Eclipse microscope (Tokyo, Japan). Migra-
ion was analysed using the ImageJ Manual tracking and Chemo-
axis tool plugins. 
For clonal proliferation assay, time-lapse images from single
ells after sorting were acquired (5 min/frame) and the number of
ell divisions in the colony formed quantiﬁed. 
Where indicated, cells were transfected with 100 nM of RNAi
gainst CD44 (Dharmacon ON-TARGET plus SMART pool #L-
 09999-0 0) using Lipofectamine 20 0 0 48 h before performing the
ssay. Gómez-Muñoz et al., CD44-high neural crest stem-like cells are 
oma tumours, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019. 
4 F.M. Vega, A. Colmenero-Repiso and M.A. Gómez-Muñoz et al. / EBioMedicine xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: EBIOM [m5G; November 2, 2019;5:54 ] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
 
d  
S  
f  
d  
l  
c  
a
5
5
n
 
e  
t  
n  
f  
e  
d  
E  
p  
h  
ﬁ  
r  
C  
M  
p  
a  
I  
s  
s  
s  
o  
i  
w
 
o  
w  
t  
S  
c  
r  
m  
e  
p  
i
5
n
 
i  
e  
W  
f  
c  
c  
d  
c  
p  
F  
e  2.8. Differentiation assay 
Differentiation of neuroblastoma cells was induced following a
modiﬁcation of the method described [30] . Cells or tumourspheres
seeded on cell culture dishes were incubated in neural low serum
media (NM media: D -MEM:F-12, 1% N2 supplement, 2% B27 sup-
plement, 1% penicillin/streptomycin) to promote neuronal differ-
entiation, NM media + 5% FBS + 10 μM Forskolin (FK, R&D) to in-
duce glial differentiation, NM media + 5 ng/ml TGF β3 (R&D) to in-
duce differentiation into mesenchymal lineage or 10 μM all-trans
retinoic acid (ATRA, Sigma), used in the clinic for differentiation
therapy. Media was replaced every 3 days for 10 days before ﬁxing
and staining the cells with appropriate markers. CD44hi cells after
cell sorting were also treated with NM media for differentiation for
6 days before ARN extraction. 
2.9. PDXs and xenograft experiments 
SK-N-SH neuroblastoma cells were resuspended in cold 5 mg/ml
Matrigel in DMEM media at a concentration of 5 ×10 6 cells/ml.
6–8 weeks old C.B-17 SCID mice (Harlan Laboratories) were in-
jected subcutaneously with 200 μl of cell suspension in the shaved
right ﬂank. Tumours formed were collected after 6–9 weeks,
minced in small pieces, dissociated in dissociation solution (HBSS
buffer + 0.05% Collagenase, 0.005% Elastase, 0.025% Trypsin and
0.04% DNAase) and incubated for 5 min in ACK buffer (155 mM
NH 4 Cl). Cells were resuspended in FACS media stained and sorted
as described into CD4 4- and CD4 4hi populations. 1–5 ×10 4 of the
sorted cells were injected in new SCID mice after recovery, follow-
ing the same procedure. Once secondary tumours appeared, they
were measured and processed for paraﬃn sectioning. 9 mice to-
tal were injected per condition. Micrometastasis analysis was per-
formed by Q-PCR detection of human cells in mouse tissue, using a
variation of the method used in [31] . Quantiﬁcation and compari-
son of the grade of metastasis was performed by a relativization of
the detected human genomic DNA to the amount of mouse tissue.
Nuclein staining in paraﬃn sections of lungs and liver tissues were
used to visualize micro metastatic clones. 
PDXs were stablished from freshly-obtained human stage 4,
neuroblastoma tumour samples. Brieﬂy, a 1 ×1 mm fragment of
original tumour was placed on a subcutaneous pocket performed
on SCID mice. Engrafted tumours were maintained in mice until
they reach a volume enough to collect new fragments and transfer
them to new recipient mice. Four different PDXs were used for the
experiments. Relevant clinical information and characteristics are
presented on Supplementary Table S2. Cells were dissociated from
early passages of these PDXs and treated as described before for TS
formation, cell sorting or cell line derivation. 
3. Statistical analysis 
Statistical analysis was performed on R2 genomics platform or
Graphpad Prism software. 
One-way (2-way on grouped differentiation data) analysis of
variance ANOVA or un-paired t -test were used for statistical anal-
ysis. Results were assumed signiﬁcant when p < 0.05. In gene ex-
pression analysis plots, box and whiskers graphs show median, 10–
90 percentiles and outliers as dots. Bonferroni test was used for the
statistical analysis on the Kaplan survival curves. In all other box
and whiskers plots, boxes show median and 25th and 75th per-
centiles and whiskers show 95% percentile. Bar graphs show aver-
age + /-SEM in all cases. Number of measurements or samples (n)
is indicated in each case. Results from cell populations after cell
sorting are expressed as mean % + / − SD. Please cite this article as: F.M. Vega, A. Colmenero-Repiso and M.A. 
associated with tumour aggressiveness and poor survival in neuroblast
10.041 . Ethics statement 
All animal experiments were conducted according to proce-
ures approved by the Ethics Committee from the Universidad de
evilla and complying with animal use guidelines. Patient samples
or the generation of the PDXs where obtained through the An-
alusian tissue Biobank after informed consent of the patients fol-
owing all stablished regulations. Clinical information on patient
ohorts for expression analysis is openly available for research use
nd has been anonymised. 
. Results 
.1. High CD44 expression correlates with poor survival in 
euroblastoma tumours 
CD44 mRNA expression has been associated with glial differ-
ntiation and good prognosis in neuroblastoma tumours [24] . Al-
hough CD44 mRNA expression is signiﬁcantly higher in low grade
euroblastoma tumours than in high stage ones, a subset of un-
avourable stage 3 and 4 neuroblastomas also presents high CD44
xpression levels. We analysed the expression of CD44 using array
atasets from a cohort of human neuroblastoma tumours ( Fig. 1 ).
ffectively, CD44 expression is signiﬁcantly lower in stage 4 com-
ared to stage 1 or 2 tumours ( Fig. 1 a). The expression of CD44 in
igh-risk neuroblastomas is inversely correlated with MYCN ampli-
cation status ( Fig. 1 b), which is in agreement with the reported
ole of MYCN as an inhibitor of CD44 transcription [17] . However,
D44 is frequently highly expressed on high-risk tumours without
YCN ampliﬁcation. We could detect high CD44-expressing sam-
les in tumours from all neuroblastoma INSS stages, benign and
ggressive, notably including also some stage 4 tumours ( Fig. 1 c).
nterestingly, patients with the highest CD44 expression among
tage 4 tumours (top 10% expressing samples from the series) pre-
ented signiﬁcantly worse outcome when compared to the rest,
howing a reduced survival ( Fig 1 d). This was true independently
f MYCN status, meaning that high CD44 expression could discrim-
nate the most aggressive patients, with worse outcome, with or
ithout MYCN ampliﬁcation. 
We were also able to detect high CD44 protein expression in
ur in-house collection of human neuroblastoma patient samples,
ith signiﬁcant presence in some aggressive, undifferentiated NB
umours, both MYCN non-ampliﬁed and ampliﬁed ( Fig. 1 e and
upplementary Table S3). CD44 + cells in these tumour sections ac-
ount for 3.8%( + / −1.1) of cells. Taken together, these observations
eveal that there is a subset of aggressive neuroblastoma tumours,
ostly but not exclusively MYCN non-ampliﬁed, with high CD44
xpression and worse survival, and suggest that CD44 might be ex-
ressed on cells other than benign differentiated glial derivatives
n neuroblastoma. 
.2. CD44 is expressed in undifferentiated, tumoursphere-forming 
euroblastoma cells 
To study CD44 expression and its role in NB cell heterogene-
ty and differentiation, we initially used the phenotypically het-
rogeneous, MYCN non-ampliﬁed, SK-N-SH neuroblastoma cell line.
e and others have used serum-rich neural crest media (NCM)
or the culture of undifferentiated neural crest-derived progenitor
ells from adult tissues and neuroblastoma. These cells grow as
lonal spheres on low adherence conditions and can be later in-
uced to differentiate [30 , 32 , 33] . We set up the culture of SK-N-SH
ells in NCM to enrich for undifferentiated cells, or in serum de-
rived NCM (NCMlow) for comparison ( Fig. 2 and Supplementary
ig. S2). NCM culture of neuroblastoma cells selects for undiffer-
ntiated tumoursphere-forming cells with higher self-renewal andGómez-Muñoz et al., CD44-high neural crest stem-like cells are 
oma tumours, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019. 
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Fig. 1. CD44 expression in human neuroblastoma tumours. a, CD44 expression in NB tumours according to INSS stage (stages 1 to 4). (ANOVA; ∗∗: p < 0.005). b, CD44 
expression in high-risk neuroblastoma tumours according to their MYCN ampliﬁcation status. ( t -test; ∗∗∗: p < 0.001). In brackets, number of tumour samples. c, Expression 
of CD44 in human neuroblastoma tumour samples sorted by INSS stage (stages 1 to 4) and showing their MYCN status (red = MYCN ampliﬁed). d, Survival curves showing 
overall survival probability for stage 4 tumours with high CD44 vs rest when considering all tumour samples (i), MYCN-ampliﬁed tumour samples only (ii) or MYCN non- 
ampliﬁed tumour samples only (iii). Patient samples per group are shown in brackets. p values: Bonferroni. e, CD44 staining on tissue samples from NB tumours with 
unfavourable histology. % of CD44 cells in tissue sample is indicated. Clinical information from these tumours can be seen on Supplementary Table S1. Bar: 200 μm. Bar on 
inset: 25 μm. Arrowhead: CD44 expressing cells. Asterisk: examples of unspeciﬁc red blood cells staining. 
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f  roliferative capacity, expressing high levels of the undifferentiated
rogenitor marker Nestin and low levels of neuronal markers like
uj1 or DDC, which are present mainly at the periphery of the tu-
oursphere (TS). The culture of this spheres on NCMlow media
rovokes a marked neuronal differentiation, best observed in cell
orphology upon adherence ( Fig. 2 a and Supplementary Movie
1). This was not exclusive for SK-N-SH cells and could be observed
lso in other neuroblastoma cell lines, like GI-M-EN, GI-CAN and
he MYCN ampliﬁed cell line SK-N-DZ (Supplementary Fig. 2 and
ata not shown). 
CD44 expression has been already described in adherent neu-
oblastoma cell lines in comparison to more neuronal and poorly
dherent cell lines [18] . Our results indicated that expression
f CD44 is almost exclusively restricted to NCM selected, non-
euronal, tumoursphere-forming cells ( Fig. 2 b). CD44 was also
ainly present in TS growing on NCM, especially in the main body
f the tumoursphere ( Fig. 2 c). Few CD44 positive cells could be
bserved in NCMlow tumourspheres, and they were always at the
ore of the sphere, and negative for DDC expression. CD44 expres-
ion was also restricted to NCM growing tumorspheres in other cell
ines (Supplementary Fig. S2d). Sympathetic noradrenergic neurob-
astic cell lines like CHLA-15 or CHLA20 did not present CD44 ex-
ression or generated undifferentiated TS in these conditions (Sup-
lementary Fig. S3b). We also analysed by RT-PCR the expression
f different CD44 splice variants on these cells but could not ﬁnd
 consistent pattern of expression among the different conditions
nd tumourspheres (data not shown). 
Some markers for stemness in neuroblastoma cells have been
roposed [34] . We decided to evaluate the expression of CD114
CSF3R), CD133 (prominin1) and CD117 (c-kit) in the context of
D44 expression in neuroblastoma cell lines ( Fig. 2 d and Supple-
entary Fig. S3c). We detected co-expression of CD44 with c-kit
nd, more importantly, with CD114, in a minor population of cells
n SK-N-SH cell line and in primary PDX derived cell lines. These
verlappings account for a considerable percentage of CD44 pos-
tive cells in the case of CD114 (ranging from 36% in the case
f SK-N-SH to 14% in the case of NB39T cells). We also detected
o-expression of CD44 and CD114 in tumorspheres derived from
D44hi cells ( Fig. 2 e). 
These observations indicate that self-renewing undifferentiated
S growing on NCM media are enriched in CD44 + cells, and that
ifferentiated DDC positive cells are negative for CD44 expression. 
.3. CD44 marks an invasive and proliferative neuroblastoma cell 
opulation 
CD44 has been suggested to mediate a metastatic proﬁle in
euroblastoma [35] and this seems to be its main role in other
olid tumours [12] . We wanted to elucidate the function of CD44
rotein in NB cells and for that we separated CD44 high expressing
CD4 4hi) and CD4 4 negative (CD4 4-) cell populations from hetero-
eneous SK-N-SH neuroblastoma cells. In agreement with a pre-
ious report [36] , an average of 39.7% ( + / −16.2) of SK-N-SH cells
ere CD44 positive in normal growing conditions (Supplementary
ig. S3a). The expression of CD44 in these cells distinguished two
eterogeneous but distinct cell populations, with morphology and
haracteristics that are maintained in culture for at least 14 days
fter sorting ( Fig. 3 a and Supplementary Fig. S4a). 
The CD44hi cell population presented increased cell adhesion
nd spreading, both onto tissue culture plastic and onto an HA-
ich extracellular matrix like Matrigel ( Fig. 3 b and Supplemen-
ary Fig. S4b). Controlled cell adhesion to extracellular matrix is
eeded for cancer cell motility and invasion, and binding of SK-
-SH cells to HA-rich matrix has been previously shown to be
D4 4-dependent [37] . CD4 4hi neuroblastoma cells are enriched in
-Actin and, when embedded on a 3D extracellular matrix, formPlease cite this article as: F.M. Vega, A. Colmenero-Repiso and M.A. 
associated with tumour aggressiveness and poor survival in neuroblast
10.041 roups that extend actin-rich protrusions (Supplementary Fig. S4a
nd c). Both presence of actin polymerization and extension of
rotrusions are indicative of a motile and invasive phenotype. Mi-
ration of CD44hi cells on a 3D environment is signiﬁcantly in-
reased compared to CD44- cells ( Fig. 3 c). Of note, adhesion, mor-
hology and migration phenotypes were only partially abrogated
fter CD44 downregulation by RNAi, indicating that CD44 marks
n adhesive cell population but other adhesion molecules could be
lso involved in the phenotype ( Fig. 3 b and c and Supplementary
ig. S4d). 
In addition, CD44hi cells seeded clonally, divide more than the
egative population ( Fig. 3 e), indicating a higher proliferative ca-
acity in vitro. 
These results show that high CD44 expression, in MYCN non-
mpliﬁed neuroblastoma cells, marks a population that interacts
etter with extracellular matrix substrates, is more motile and pro-
rusive in 3D, and proliferates faster than CD44- cells. 
.4. CD44hi tumoursphere-forming neuroblastoma cells behave as 
eural crest-like multipotent progenitor cells in culture 
Neural crest progenitors give rise to clonal TS in low adher-
nce conditions, from which differentiated cells, corresponding to
ifferent neural crest-derived lineages, can be obtained. In order
o explore the nature of CD44hi neuroblastoma cells, we tested
he tumoursphere forming ability of CD44hi and CD44- cells. The
D44hi cell population is enriched in tumoursphere-forming cells
accounting for 1% of the sorted CD44hi cells) with higher prolifer-
tive potential, reﬂected on an increased TS diameter ( Fig. 4 a). Sin-
le cells sorted on ultra-low binding 96 well plates gave the same
esults, demonstrating clonogenicity of the formed tumourspheres
 Fig. 4 b). These spheres were mainly composed by CD44 + /Nestin +
ells (bottom panel on Fig. 4 b). Same results could be observed
ith PDX-derived cells (Supplementary Fig. S5a) 
Gene expression analysis showed that CD44hi-derived TS ex-
ress higher levels of undifferentiation markers compared to
D44- cell-derived TS ( Fig. 4 c). Analysis of available expression
atasets shows that CD44 expression is signiﬁcantly higher on
eural crest cells or mesenchymal-undifferentiated (mes) neurob-
astoma cells compared to adrenergic (adr) neuronal-like ones
 Fig. 4 d). Moreover, CD44hi cells have an increase in mes/neural-
rest-like gene expression signature, further reinforcing the con-
ection between CD44 expression and the undifferentiated pheno-
ype ( Fig. 4 e and Supplementary Fig. S5b). This expression pattern
an be reversed after neuronal differentiation, with a drop in mes
ignature genes and an increase in adr signature genes ( Fig. 4 e). 
While tumourspheres formed from CD44- neuroblastoma cells
ere mainly composed of DDC + /S100 β low/Nestin low neurob-
asts, TS coming from sorted CD44hi cells were composed mostly
y CD44hi/Nestin high undifferentiated cells ( Fig. 5 a). Furthermore,
ome DDC + and GFAP + cells could be seen at the periphery of
D44hi cell-derived TS, indicating that CD44 positive cells could
ive rise to neural derivatives. 
To further show that CD44hi tumoursphere-forming cells were
ultipotent, we decided to direct their differentiation into all three
ineages typically obtained from sympatho-adrenal neural crest
recursors, following a modiﬁcation of the protocol described else-
here [30] ( Fig. 5 b and Supplementary Fig. S5c). Culturing in neu-
al low-serum media (NM) promotes neuronal differentiation, the
ddition of Forskolin (FK) enriches the culture in glial cells, and
he presence of TGF β3 promotes differentiation of neural crest
ells into the mesenchymal lineage. We have also used all-trans
etinoic acid (ATRA), commonly used in the clinic as a differen-
iation agent for neuroblastoma treatment. Independently of the
reatment applied, we observed mostly neuronal differentiation
rom CD44- cells, measured by the expression of DDC and Tuj1.Gómez-Muñoz et al., CD44-high neural crest stem-like cells are 
oma tumours, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019. 
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Fig. 3. CD44 marks a motile and proliferative NB cell population. a, Representative dot-plot of SK-N-SH cells labelled for CD44 showing FACS-sorted populations. Immunos- 
taining show sorted cells 7 days after sorting. Bar: 50 μm. b, Adhesion of the indicated cell populations onto different substrates. Measures show number of cells adhered 
relative to the levels observed on CD44hi population over plastic condition (set at 100%). (ANOVA; ∗: p < 0.05, ∗∗: p < 0.01). c, Velocity and distance reached by cells from 
the indicated cell populations in 3D migration assays. ( t -test; ∗∗: p < 0.01). d, Velocity and distance reached by cells from the indicated cell populations in 2D migration 
assays. ( t -test; ∗: p < 0.01). e, Number of cell divisions per each colony, starting from a single cell with the indicated phenotypes. Line indicates median. ( t -test; ∗∗: p < 0.01). 
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m  This conﬁrms our previous observations indicating that CD44- cells
were mostly restricted to the neuronal lineage. On the other hand,
tumourspheres from CD44hi precursor cells also gave rise to DDC +
neuronal cells, demonstrating that not all CD44 + cells are differ-
entiated glial derivatives, and that CD44hi undifferentiated cells
retain neuronal differentiation capacity. Moreover, these TS were
also able to produce glial (S100 β+ ) and mesenchymal ( αSMA + )
derivatives when induced to differentiate with the appropriate me-
dia, demonstrating their multipotent potential ( Fig. 5 b). The dis-
tinct capacity of CD44hi-derived TS to differentiate towards both
mesenchymal and neuronal lineages was further demonstrated by
the differentiation of TS coming from sorted single cells (Supple-
mentary Fig. S5d and e). Please cite this article as: F.M. Vega, A. Colmenero-Repiso and M.A. 
associated with tumour aggressiveness and poor survival in neuroblast
10.041 In conclusion, these results show that a small proportion of
D44hi cells in neuroblastoma seem to be neural crest-derived
ultipotent progenitors able to give rise to diverse cell types. 
.5. CD44hi neuroblastoma tumour cells are more tumorigenic and 
etastatic 
High-grade neuroblastomas are vascularized tumours, whose
ajor component are proliferative neuroblasts. Rare, non neu-
oblastic cell populations are also present in these tumours, but
heir contribution to tumour aggressiveness is not clear. To ex-
lore the contribution of undifferentiated CD44 positive cells to tu-
our formation we sorted CD44hi and negative cells from primaryGómez-Muñoz et al., CD44-high neural crest stem-like cells are 
oma tumours, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019. 
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Fig. 4. CD44hi tumoursphere-forming NB cells have an undifferentiated/neural crest-like identity. a, Representative images and quantiﬁcation of forming eﬃciency and 
diameter of TS from CD4 4hi and CD4 4- sorted cells. ( t -test; ∗∗: p < 0.01). Bar: 200 μm. b, Representative images and quantiﬁcation of TS-forming eﬃciency on a single cell 
sorting assay. Data is from 2 independent experiments with a total of 960 sorted cells per condition. ( t -test; ∗: p < 0.05). Bar: 50 μm. c, Gene expression of representative 
undifferentiation (Bmi1, Nes and OCT3/4) and differentiation (TH) marker genes on TS derived from CD44hi cells, relative to the expression of CD44 negative-derived TS. d, 
CD44 expression from data in GEO ID: GSE90805 on transcriptionally deﬁned adrenergic neuronal-like (22 cell lines) or mesenchymal undifferentiated neuroblastoma cell 
lines (7 cell lines), and human neural crest cells (5 cell lines). (ANOVA; ∗∗: p < 0.01). e, Relative gene expression in CD44hi cells compared to CD44- or to CD44hi cells after 
differentiation, as indicated. Genes corresponding to ADR signature or MES signature are indicated. f.c.: fold change. Diff: differentiation. 
Please cite this article as: F.M. Vega, A. Colmenero-Repiso and M.A. Gómez-Muñoz et al., CD44-high neural crest stem-like cells are 
associated with tumour aggressiveness and poor survival in neuroblastoma tumours, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019. 
10.041 
10 F.M. Vega, A. Colmenero-Repiso and M.A. Gómez-Muñoz et al. / EBioMedicine xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: EBIOM [m5G; November 2, 2019;5:54 ] 
Fig. 5. CD44hi TS-forming cells are multipotent. a, Immunostaining showing the indicated markers on secondary tumourspheres sections from CD44hi or CD44- sorted 
SK-N-SH cells. Arrowheads: DDC positive cells in TS formed from CD44hi cells. Asterisks: GFAP positive cells in TS formed from CD44hi cells. Bar: 50 μm. b, CD44-sorted 
SK-N-SH neuroblastoma cells after treatment with different media, as described in the methods section, and stained with the indicated markers. DAPI is used in all images 
for nuclear staining. Arrowheads point to αSMA positive cells in TGF β3 treated cells. Graphs show quantiﬁcation of positive cells for each marker and condition. (ANOVA; ∗: 
p < 0.05, ∗∗∗: p < 0.001), ns: not signiﬁcant. Bar: 50 μm. 
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f  xenografts performed on immune-compromised mice and injected
them on secondary recipient mice (Supplementary Figs. S6a and
b). SK-N-SH cells form neuroblastic tumours that recapitulate, his-
tologically and morphologically, human neuroblastomas [35] , and
that present a low proportion of CD44 positive cells (7.1 + / −6.8%
of CD4 4 + cells). CD4 4 positive cells sorted from these tumours
generated secondary tumours more eﬃciently, and more aggres-
sively than CD44 negative cells ( Fig. 6 a and b). These tumours
also metastasize more frequently and aggressively to the lungs
( Fig. 6 c). CD44hi cells-derived tumours have the same histologic
characteristics that the ones formed by the unsorted population
and were composed mainly of CD44 negative neuroblasts, withPlease cite this article as: F.M. Vega, A. Colmenero-Repiso and M.A. 
associated with tumour aggressiveness and poor survival in neuroblast
10.041  24.2% ( + / −12.9) of CD44 positive cells. Interestingly, xenografts
ormed by CD44- tumour cells also presented a CD44 + population
14 + / −1.4% of CD44 + cells within the tumours) suggesting some
lasticity in vivo. These cells continue forming undifferentiated tu-
ourspheres in culture with higher eﬃciency than CD44 negative
ells sorted from the same tumours ( Fig. 6 d and Supplementary
ig. S6c). 
Finally, we sorted freshly dissociated cells from neuroblas-
oma patient derived xenografts (PDXs) growing in immune-
ompromised mice (Supplementary Fig. S6d). When re-injected in
ecipient mice, CD44hi cells generated highly vascularized undif-
erentiated neuroblastic tumours with higher eﬃciency than CD44Gómez-Muñoz et al., CD44-high neural crest stem-like cells are 
oma tumours, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019. 
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Fig. 6. CD44hi cells present increased tumorigenic potential. a, Representative xenograft obtained after SK-N-SH engraftment, stained for CD4 4. Arrowheads: CD4 4 positive 
cells. Bar: 100 μm. b, Volume of the appeared tumours and incidence obtained at 8 weeks after injection with the indicated cell populations. ( t -test; ∗: p < 0.05). c, Incidence 
and extent of micrometastasis in lungs and liver of xenografted mice. Representative immunostainings showing micrometastatic colonies of human cells in lungs are shown. 
Arrowheads: NB cell colonies. Bar: 100 μm. d, Immunostaining of sectioned tumourspheres from CD44hi and CD44- sorted cells from tumours. Bar: 50 μm. e, PDX tumour 
volume and incidence obtained at 8 weeks after injection with the indicated cell populations. ( t -test; ∗: p < 0.01). f, Representative images of paraﬃn sections from tumours 
obtained from CD44hi or CD44- PDX cells, stained with the indicated antibodies. Bar: 100 μm (200 μm for αSMA images). ( t -test; ∗: p < 0.05). g, Representative confocal 
image from PDX tissue section stained for CD44, Nestin and S100 β . White arrowhead points to a CD44 + /Nes + /S100 β- cell. Yellow arrowhead points to a CD44 + /Nes-/S100 β
cell. Bar: 50 μm. 
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n  egative cells ( Fig. 6 e and f and Supplementary Fig. S6e). Exam-
ning the histology of these PDX tumours in detail, we could de-
ect CD44 + /Nes + cells and CD44 + /S100 β+ elongated cells with
chwannian morphology ( Fig. 6 g), with Nes and S100 β staining be-
ng mutually exclusive, corroborating the existence of two distinctPlease cite this article as: F.M. Vega, A. Colmenero-Repiso and M.A. 
associated with tumour aggressiveness and poor survival in neuroblast
10.041 D44 + cell populations and the presence of CD44 + undifferenti-
ted cells. Of note, CD44 expression was restricted to the mem-
rane in CD44 + /Nes + cells. 
Altogether, our in vivo data suggest that CD44 marks, both in
euroblastoma cell line-derived xenografts and in human PDXs, aGómez-Muñoz et al., CD44-high neural crest stem-like cells are 
oma tumours, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019. 
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C  tumorigenic undifferentiated cell population, able to form neurob-
lastic aggressive tumours upon re-injection into secondary recipi-
ent mice. 
6. Discussion 
We show here that CD44 is expressed in a cell population
with characteristics of undifferentiated neural crest-like progen-
itors, which are able to give rise to multipotent tumourspheres
in culture and present a high tumorigenic potential. There has
been some controversy over the signiﬁcance of CD44 expression
in neuroblastic tumours, with some studies describing that CD44
expression can be a signiﬁcant factor for the prediction of sur-
vival in neuroblastomas, associated with good prognosis [25] . How-
ever, most studies classify tumour patient samples as CD44 pos-
itive when more than 10% of the cells are immune-reactive for
anti-CD44 antibodies in immunohistochemistry, ignoring less fre-
quent cell populations. Moreover, they do not normally address
CD44 active membrane localization or the level of expression. A
study performed on dissociated tumour cells showed CD44 ex-
pression upregulation in non-MYCN human NB metastatic tumours
with unfavourable histology, compared to benign ones [38] . Our re-
sults also suggest that, among high-risk NB tumours, a high CD44
expression confers worse survival, and that this CD44 expression
could be indicative of the presence of undifferentiated neural crest-
like cells with malignant properties, different than the neuroblas-
tic adrenergic population that normally forms the bulk of the tu-
mour. Recent works have suggested a similar cellular heterogeneity
on high-grade neuroblastoma tumours at the transcriptional level
[ 10 , 11 ]. 
The presence of CD44 is frequently associated with differenti-
ated tumours with higher glial and stromal content (schwannian
subtype) and therefore with a better prognosis [ 18 , 23 ]. This is the
case for most low stage, MYCN non-ampliﬁed tumours and ex-
plains previous observations on those tumours. However, there is
still a subset of NB patients with no ampliﬁcation of MYCN that
progresses badly and is more diﬃcult to classify. Our results show
that a high CD44 expression could also be associated with tumours
with worse outcome and presence of undifferentiated cells, with
invasive and proliferative properties, that could contribute to tu-
mour aggressiveness. The characterization of CD44 expressing cells
in these tumours could be of help for the early detection and treat-
ment of patients. 
The expression of CD44 shows an inverse correlation with
MYCN oncogene expression [18] . This introduces diﬃculties to the
study of the role of CD44 in neuroblastoma tumours, as MYCN am-
pliﬁcation is a strong predictor and driver of aggressiveness. How-
ever, event-free survival probability among patients with high-risk
decreases in case of high CD44 expression, both in MYCN non-
ampliﬁed or ampliﬁed tumours, illustrating how CD44 could be in-
dicative of the presence of undifferentiated malignant cells in these
tumours, and further highlighting the different meanings of CD44
expression in NB. 
Our data conﬁrm that CD44hi NB cells have increased adhesion
and migration, likely contributing to their aggressiveness. CD44 +
cells have been shown to express more adhesion molecules than
CD44- cells in NB [36] . However, we only get partial suppres-
sion of these phenotypes after CD44 expression knockdown, indi-
cating that there might be other adhesion molecules implicated.
Nevertheless, cell sorting of NB cells based on CD44 expression
is enough to identify this motile and adhesive cell population. A
differential metastatic pattern in CD44 + cell-induced NB tumours,
and the accumulation of CD44 + NB cells in hyaluronic-rich areas
of the lungs after metastatic dissemination have been suggested
[ 35 , 37 ]. Our xenograft experiments show an increase in metastasis,
speciﬁcally to the lungs, in CD4 4hi-derived tumours. Matrix-CD4 4Please cite this article as: F.M. Vega, A. Colmenero-Repiso and M.A. 
associated with tumour aggressiveness and poor survival in neuroblast
10.041 nteraction has been linked to increased tumour cell survival, in-
reased epithelial-to-mesenchymal transition (EMT) and metasta-
is, cancer stem cell self-renewal and drug resistance [39] . Metas-
asis in neuroblastoma might be deﬁned by an adhesion imbalance
n the tumour microenvironment [40] . The direct contribution of
he migratory and adhesive properties of CD44 + cells to NB metas-
asis and aggressiveness remains to be elucidated. 
We have shown that CD44hi cells sorted from cell lines, mouse
enografts or PDXs, are able to form multipotent undifferentiated
umourspheres with increased proliferative and self-renewal ca-
acity. The origin of neuroblastoma is thought to be an incom-
letely differentiated neural crest precursor during development
 1 , 41 ]. The existence of cells with stem-like properties in NB tu-
ours has been suggested and their possible contribution to tu-
our aggressiveness proposed [ 38 , 42–44 ]. Nevertheless, the dis-
overy of a deﬁnitive marker allowing the isolation and characteri-
ation of this cell population in tumours has been elusive [43] and
ost probably a combination of cellular markers in speciﬁc can-
er settings will be needed [ 45 , 46 ]. CD44 permits the enrichment
or cancer stem cells (CSCs) in tumours of diverse origin [ 39 , 47 ],
nd promotes tumour progression by mediating CSC-driven metas-
asis [48] . Our results point to CD44 as a marker for tumour cells
ith shared characteristics with neural precursors. CD44 expres-
ion in neural precursor cells improves transendothelial migration
nd invasion [49] and it has been detected in normal neuronal pre-
ursors migrating into the adrenal gland [50] . In a transcriptome
roﬁle study with normal embryonic neuroblasts, CD44 appeared
ore expressed in these primordial cell clusters, putative origin of
euroblastomas, than in control adjacent cortical cells [51] . Our re-
ults suggest that CD44 might be a non-exclusive marker for undif-
erentiated neural crest stem-like cells in neuroblastoma, although
ts expression in other differentiated cell populations within tu-
ours, as in glial S100 β+ derivatives, preclude the use of CD44 in
olitary for the identiﬁcation of these cells in this type of cancer.
he co-expression of CD44 with putative neuroblastoma stem cell
arkers, like CD114 or c-kit, described here, opens new possibil-
ties to isolate undifferentiated subpopulations from tumours. In-
erestingly, we have detected CD44 + /Nestin + /S100 β- cells in PDX
umours in which CD44 pattern of expression in the membrane is
ompatible with an active adhesive function. These cells present a
learly different morphology than CD44 + /Nestin-/S100 β+ schwan-
ian cells. 
Cellular heterogeneity has emerged has a hallmark for NB tu-
ours. Histology describes cells with different differentiation sta-
us and cells with morphology and expression patterns reminiscent
f neural crest-derived lineages [ 7 , 8 ]. Recent transcriptional and
xpression proﬁles have deﬁned the presence of at least a mes-
nchymal neural crest-like undifferentiated identity and an adren-
rgic differentiated identity, both proliferative and able to inter-
onvert to some extent [ 10 , 11 ]. Although the contribution of the
ifferent cell populations to tumour progression needs to be de-
ned, undifferentiated cells might be more malignant and resis-
ant to chemotherapy. Our results conﬁrm that CD44 is a marker
or the undifferentiated neural crest-like cell population, delin-
ating the mesenchymal/neural crest-like state from the adrener-
ic state in NB cells. It will help to deﬁne the contribution of
hese cells to NB aggressiveness. Our experiments also indicate
hat there is heterogeneity in the tumour forming ability within
he CD44hi cell population growing in normal culture conditions.
early 40% of SK-N-SH cells are positive for CD44 expression in
ulture, although only about 7% of cells are CD44 + in SK-N-SH-
erived xenografts. We found evidences of higher tumorigenicity
n CD44hi cells sorted from tumour xenografts either derived from
ell lines or from human tumour samples. Our results also show
hat, consistent with previous reports [36] , there are tumorigenic
D44 negative tumourspheres-forming progenitors on our cellGómez-Muñoz et al., CD44-high neural crest stem-like cells are 
oma tumours, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019. 
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 ultures. However, these cells seem to lack multipotency and seem
o differentiate early in vitro to neuron-like cells. 
In conclusion, we have characterized CD44 function in neurob-
astoma tumours at the cellular level, taking into consideration NB
ellular intratumoural heterogeneity and its contribution to tumour
rogression. We propose that, in NB tumours, a high CD44 expres-
ion marks a proliferative, multipotent undifferentiated cell popu-
ation with tumorigenic potential, in addition to labelling other dif-
erentiated benign cell types, explaining the different association of
D44 expression with patient survival. Our data stablishes CD44 as
 possible biomarker with prognostic value for a subset of patients.
oreover, it points to a signiﬁcant contribution of undifferentiated
D44hi precursors to neuroblastoma aggressiveness and opens the
ay to the design of strategies for their identiﬁcation and targeting
n neuroblastoma patients. 
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